Advancing foundational research from UCLA and Migal – Galilee Research Institute, ImmPact is working on T-cell therapies for liquid and solid cancers.

ImmPact Bio, a US-based developer of cancer treatments based on research at University of California, Los Angeles (UCLA) and Migal – Galilee Research Institute, picked up $111m in a series B round yesterday.

VenBio Partners, Foresite Capital and Decheng Capital led the round, in which pharmaceutical firms Bukwang Pharmaceutical and Novartis – the latter through its Novartis Venture Fund – also took part.

Additional investors included Surveyor Capital, OrbiMed and RM Global Partners (RMGP).

ImmPact Bio is working on chimeric…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email Linked in